IFRX — InflaRx N.V.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1708688 ·
Last close
$1.15
Market Cap
$169.47M
52W High
$2.95
52W Low
$0.80
ADV30
1,009,562
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 0 -5,504,916 -2,439,960 161,318,630 81,344,593 17,216,034
Jun 2026 0 0 -7,002,727 -10,648,484 166,907,332 146,567,894 20,723,760
Mar 2026 0 0 -7,208,150 -5,592,649 48,889,811 14,993,792 11,999,608
Dec 2025 -33,931 -4,892,342 -12,856,841 -10,642,393 55,216,297 16,022,171 13,659,516

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,701,111
Investing CF
$-33,917,750
Financing CF
$125,642,943
CapEx
$-102,771
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.37
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-396,507,094
Inventory
$0
Receivables
$1,124,899
ST Investments
$34,058,998
EBIT TTM
$-29,175,913
Pretax Income TTM
$-29,236,921
Interest Exp TTM
$61,008
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$-10,101
EBITDA
$-35,641,328
Free Cash Flow
$-4,312,136
Enterprise Value
$150,318,272
Total Cash
$158,514,496
Total Debt
$833,179
Shares Out
147,368,221
Trailing EPS
$-0.58
Book Value
$1.15
ROE
-38.5%
ROA
-18.5%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 29,331 -48,256,974 -45,633,780 55,216,297 13,659,516 41,556,781 -35,314,328
Dec 2024 165,789 -52,905,579 -46,064,402 76,018,457 14,602,418 61,416,040 -48,556,690
Dec 2023 63,089 -44,594,856 -42,667,529 120,208,551 17,626,821 102,581,731 -37,812,966
Dec 2022 0 -32,237,867 -29,484,611 102,399,660 14,050,220 88,349,440 -33,742,817

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.40

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.00 · spot: $1.11 · call volume: 6 · put volume: 94
Expected Move to 2027-01-15: ±$1.04 (93.24%) — implied range $0.07 – $2.15 · ATM straddle on $1.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KRRO Korro Bio, Inc. $169.10M $12.32 —
ORMP ORAMED PHARMACEUTICALS INC. $168.29M $3.87 —
ELDN Eledon Pharmaceuticals, Inc. $167.23M $1.98 —
PYXS Pyxis Oncology, Inc. $172.24M $1.44 —
SLGL Sol-Gel Technologies Ltd. $172.97M $52.83 —

News headlines (Yahoo Finance, 1h cache)

Here's Why InflaRx (IFRX) Is a Great 'Buy the Bottom' Stock Now
2026-11-13 13:55 · Yahoo
Down 20.3% in 4 Weeks, Here's Why You Should You Buy the Dip in InflaRx (IFRX)
2026-11-12 13:35 · Yahoo
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
2026-11-06 12:30 · Yahoo
InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials
2026-11-03 17:14 · Yahoo
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
2026-11-03 12:00 · Yahoo
InflaRx Announces November Investor Events
2026-10-27 11:30 · Yahoo
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
2026-10-22 16:00 · Yahoo
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
2026-10-02 11:30 · Yahoo
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
2026-10-01 11:30 · Yahoo
InflaRx Announces Participation in September Investor Conferences
2026-08-20 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.